Key result
AVEIR leadless pacemaker implantation via IJV achieves 94% success with no short-term vascular complications.
Why the study?
Data on the safety and feasibility of implanting the relatively larger AVEIR leadless pacemaker through the jugular vein were limited.
Is AVEIR ventricular leadless pacemaker implantation via the internal jugular vein safe and feasible in patients requiring single chamber pacing?
Observational (n=18)
No
Is AVEIR ventricular leadless pacemaker implantation via the internal jugular vein safe and feasible in patients requiring single chamber pacing?
AVEIR ventricular leadless pacemaker implantation via the internal jugular vein is safe and feasible, with stable electrical performance during short-term follow-up.
Supports jugular AVEIR feasibility in select cases; leaves open need for larger prospective validation of safety and durability.
Background The jugular approach for Micra leadless pacemaker (LP) implantation offers potential advantages over the femoral route, however data on safety and feasibility for the relatively larger AVEIR LP implantation through the jugular vein is limited. This study evaluated the procedural safety and short‐term clinical outcomes of AVEIR ventricular LP implantation via the internal jugular vein (IJV). Methods All consecutive patients undergoing AVEIR LP implantation via the IJV at our center between November 2023 and July 2025 were included. Procedural details, device electrical parameters and complications were collected from patient electronic records. Results Eighteen patients (median age 76 years, 33% female) had an AVEIR LP implantation via the IJV. Implantation was successful in 17/18 patients (94%). The median duration of the procedures was 65.5 min (45.0–134.0) with a median fluoroscopy time of 11.2 min (7.4–42.3). Median follow‐up time was 9.9 months (0.6–19.5). During follow up the device electrical parameters remained stable with, mean R‐wave amplitude 8.83 mV ± 3.6, pacing threshold 0.75 V. ± 0.4 V and impedance 730 ± 338 Ω; with an average estimated battery longevity of 16.0 ± 4.5 years. Two minor procedural complications occurred: one requiring conversion to femoral access, and one requiring an additional transvenous pacemaker lead due to elevated pacing thresholds. No vascular complications were observed. Conclusion AVEIR ventricular LP implantation via the IJV is safe and feasible, with stable electrical performance, during short‐term follow‐up. While the larger device size may challenge AVEIR implantations in smaller hearts, using the delivery sheath as a support to create a sharper curve facilitates the procedure.
No takes yet. Share an insight, caveat, or question.
Saleem‐Talib et al. (2026) conducted an observational in Indication for leadless pacemaker (n=18). AVEIR leadless pacemaker implantation via the internal jugular vein was evaluated on Procedural safety and short-term clinical outcomes (successful implantation). AVEIR leadless pacemaker implantation via the internal jugular vein was successful in 94% of patients (17/18), with stable electrical performance and no vascular complications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: